Intravascular Ultrasound Articles & Analysis

9 news found

ELIXIR MEDICAL COMPLETES ENROLLMENT IN BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM

Impact of peri-stent remodeling on restenosis: a volumetric intravascular ultrasound study. Circulation. 2001;103(17):2130-2132. doi:10.1161/01.cir.103.17.2130 Maier, W, Windercker, S, Kung, A, et al. ...

Feb. 15, 2022

ByElixir Medical Corporation

ELIXIR MEDICAL EXPANDS BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM

Apr. 22, 2021

ByElixir Medical Corporation

ELIXIR MEDICAL ANNOUNCES COMMENCEMENT OF INFINITY-SWEDEHEART RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM

Mar. 16, 2021

ByElixir Medical Corporation

ELIXIR MEDICAL ANNOUNCES OUTSTANDING 24-MONTH DATA FOR DYNAMX CORONARY BIOADAPTOR SYSTEM, DEMONSTRATING STRONG SAFETY WITH NO TARGET LESION REVASCULARIZATION, MYOCARDIAL INFARCTION OR THROMBOSIS THROUGH 24 MONTHS

Jan. 27, 2021

ByElixir Medical Corporation

ELIXIR MEDICAL ANNOUNCES FIRST PATIENT TREATED IN BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM

Jan. 13, 2021

ByElixir Medical Corporation

Results of the PROSPECT II Natural History Study Demonstrate High-Risk Plaques Identified by NIRS+IVUS Imaging are Linked to Future Coronary Events

Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced positive results from the PROSPECT II and PROSPECT ABSORB studies, presented today as a late-breaking clinical trial at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. The PROSPECT II study demonstrated the ability of ...

Oct. 14, 2020

ByInfraredx, Inc.

FFR-SEARCH Shows Clear Trend Towards Major Adverse Cardiac Events with Lower FFR

Suboptimal physiological results can often occur when relying on angiographic imaging alone, however, further testing using an FFR pullback or intravascular imaging can identify opportunities to optimize and ultimately improve the patient outcome. ...

Jun. 20, 2019

ByACIST Medical Systems

Infraredx, a Nipro Company, Announces FDA Approval of Expanded Label Claim for the Makoto Intravascular Imaging System

Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the indications for use for its Makoto Intravascular Imaging System. The approval is based on the results of the landmark Lipid-Rich Plaque (LRP) Study, ...

Apr. 22, 2019

ByInfraredx, Inc.

Landmark Lipid-Rich Plaque (LRP) Study Results Demonstrate the Ability to Accurately Identify Patients and Plaques at Risk for Major Coronary Events

Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, presented late-breaking clinical trial results for its landmark Lipid-Rich Plaque (LRP) Study today at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. ...

Sep. 24, 2018

ByInfraredx, Inc.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you